Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

April 2025

VYUHPHARMA Akesobio Akeso's ivonescimab combined with chemotherapy, shows statistically significant and positive Phase 3 results in the first-line treatment of sq-NSCLC compared to tislelizumab with chemotherapy (Clinical data, Phase 3) REPERTOIRE R Repertoire Immune Medicines has partnered with Genentech to develop T cell-targeted immune therapies for autoimmune diseases using the DECODE platform DAAN DAAN Biotherapeutics has signed an exclusive licensing agreement with GC Cell for a tumor antigen-specific antibody sequence in CAR-T and CAR-NK therapy development (collaboration) (Agreement) All logos and trademarks remain the intellectual properties of their respective owners

📢 Highlights from April 21 to 25 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from April 21 to 25 in the world of pharma and healthcare! 🗞️👀 Read More »

Q1 2025 Earnings Call April 28,2025 To May 02,2025 April 29 April 30 Pfizer NOVARTIS GSK Biogen Biogen BAUSCH Health AstraZeneca REGENERON Otsuka dorsia May 01 AMGEN Alkermes moderna Lilly ORGANON Visit our website for more updates | www.vyuhpharma.com

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 28–May 01. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 28–May 01. 💻 Read More »

Vyuhpharma Celltrion (FDA, Phase 3) Celltrion's YUFLYMA receives FDA interchangeable designation, supported by positive Phase 3 study data for moderate-to-severe plaque psoriasis Wayfinder Bioscinces + Daiichi Sankyo (Collaboration) "Wayfinder and Daiichi Sankyo have announced an R&D collaboration in neurodegeneration Eli Lilly (Clinical data, Phase 3) Lilly's oral GLP-1, orforglipron, has met its primary endpoints in a Phase 3 trial, demonstrating significant efficacy and safety comparable to injectable GLP-1 therapies Sanofi + Earendil Labs (Agreement) "Earendil Labs and Sanofi have entered into a license agreement for two potential first-in-class bispecific atibodies, HXN-1002 and HXN-1003, targeting autoimmune and inflammatory bowel diseases All logos and trademarks remain the intellectual properties of their respective owners

📢 Highlights from April 14 to 18 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from April 14 to 18 in the world of pharma and healthcare! 🗞️👀 Read More »

INVESTOR CALENDER OF THE WEEK Q1 2025 Earnings Call Annual Meeting of Shareholders Annual General Meeting April 23 April 24 April 25 Thermo Fisher SCIENTIFIC Pfizer MERCK April 24 Roche MERCK CHAINSA April 25 Bristol Myers Squibb sanofi GILEAD B A BAYER ER April 25 abbvie Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 21–25. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 21–25. 💻 Read More »

Q1 2025 EARNINGS CONFERENCE CALL April 16 Abbott All logos and trademarks remain the intellectual properties of their respective owners

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 16. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 16. 💻 Read More »

AbbVie ( EC, Approval ) European Commission Approves AbbVie's RINVOQ® (upadacitinib) for Treatment of Giant Cell Arteritis in Adults Johnson & Johnson ( Clinica data, Phase 3) Johnson & Johnson highlights 18-Month data from its Phase 3 Vivacity-MG3, demonstrating nipocalimab’s sustained reduction in IgG antibodies and continued improvement in gMG symptoms Johnson & Johnson + Halozyme Therapeutics ( EC, Approval) European Commission grants approval for Johnson & Johnson's SC RYBREVANT® with ENHANZE® in patients with advanced EGFR-mutated non-small cell lung cancer Remegen ( Clinica data, Phase 3) Remegen reports positive topline Phase 3 data for telitacicept in gMG: 98.1% achieve clinically meaningful MG-ADL improvement; 87% show QMG score reduction at week 24 Avidity Biosciences ( Ophan Drug Designation ) Avidity Biosciences secures Orphan Drug Designation in Japan for delpacibart etedesiran, supporting ongoing development in myotonic dystrophy type 1

📢 Highlights from April 07 to 11 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from April 07 to 11 in the world of pharma and healthcare! 🗞️👀 Read More »

Vyuhpharma ResVita Bio (FDA, Orphan Drug Designation) ResVita Bio receives FDA orphan drug esignation for RVB-003 to treat netherton syndrome Novartis (FDA) Novartis receives FDA accelerated approval for VANRAFIA® to reduce proteinuria in IgA nephropathy ESTEVE (Agreement) ESTEVE signs global license and supply agreement with Eton pharmaceuticals for INCRELEX®, excluding the USA Flagship (Partnership) Flagship Pioneering partners with Pfizer to develop novel selective inhibitors for autoimmune diseases GRIN Therapeutics (EmA, PRIME Designation) GRIN Therapeutics granted EMA PRIME designation for Radiprodil in GRIN-related neurodevelopmental disorder

📢 Highlights from April 01 to 06 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from April 01 to 06 in the world of pharma and healthcare! 🗞️👀 Read More »

INVESTOR CALENDER OF THE WEEK April 09,2025 Το April 11,2025 24th Annual Needham Virtual Healthcare Conference Annual General Meeting April 09 April 11 Jazz Pharmaceuticals. Alkermes AstraZeneca Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 07–11. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 07–11. 💻 Read More »

Roche's Virtual Neurology Investor Event April 04 Roche Visit our website for more updates I www.vyuhpharma.com

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 01–04. 💻

Uncategorized / YASHASWINI N

📢Attention ⏰Stay up-to-date with the latest investor calls by checking out our calendar for April 01–04. 💻 Read More »

Vyuhpharma Sungen (FDA, FTD) FDA grants Fast Track designation to Sungen Biomedical's SGC001 mAb for acute myocardial infarction Sermonix + Regor (Partnership) Sermonix and Regor partner to enhance rCARD platform for advancing breast oncology therapeutics Palatin (FDA, ODD) FDA grants Orphan Drug Status to Palatin's PL7737 for treating obesity from leptin receptor deficiency Vast (FDA, QIDP) FDA grants QIDP designation to Vast's ALX1 for targeting pseudomonas and other critical pathogens

📢 Highlights from March 24 to 31 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢 Highlights from March 24 to 31 in the world of pharma and healthcare! 🗞️👀 Read More »

Search

Recent Posts

Highlights from the Week of 21st Sep – 28th Sep in the world of pharma and healthcare!
Attention stay up to date with the latest investor calls by checking out our calendar for the week of Sep 22,2026 To Sep 23,2026
Highlights from the Week of 14th Sep – 21st Sep in the world of pharma and healthcare!
Attention stay up to date with the latest investor calls by checking out our calendar for the week of September 14,2026 To September 15,2026
Highlights from the Week of 07th September – 14th September in the world of pharma and healthcare!

Recent Comments

No comments to show.

Archives

September 2026
August 2026
July 2026
June 2026
May 2026
April 2026
March 2026
February 2026
January 2026
December 2025
November 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
March 2025
February 2025
January 2025

Categories

Uncategorized

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of Use

Privacy Policy

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message